The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ITGB6 as an inhibitor of T-cell killing via modulation of paracrine TGFβ signaling in pancreatic ductal adenocarcinoma.
 
William J. MacDonald
No Relationships to Disclose
 
Maximilian Schwermann
No Relationships to Disclose
 
Praveen Srinivasan
No Relationships to Disclose
 
Vida Tajiknia
No Relationships to Disclose
 
Wafik S. El-Deiry
Stock and Other Ownership Interests - Chimerix; Oncoceutics; p53-Therapeutics; SMURF-Therapeutics
Consulting or Advisory Role - Rain Therapeutics
Research Funding - Chimerix; D&D Pharmatech
Patents, Royalties, Other Intellectual Property - Patent on therapeutic targeting on hypoxia-inducible factors; Patent on TIC10 (ONC201); Patents pending on the use of small molecules to target mutant p53
Other Relationship - Caris Life Sciences
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences